Biotage AB
STO:BIOT

Watchlist Manager
Biotage AB Logo
Biotage AB
STO:BIOT
Watchlist
Price: 155 SEK 2.58% Market Closed
Market Cap: 12.3B SEK
Have any thoughts about
Biotage AB?
Write Note

Biotage AB
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Biotage AB
Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Biotage AB
STO:BIOT
Cash Equivalents
kr370m
CAGR 3-Years
1%
CAGR 5-Years
23%
CAGR 10-Years
17%
AddLife AB
STO:ALIF B
Cash Equivalents
kr272m
CAGR 3-Years
8%
CAGR 5-Years
35%
CAGR 10-Years
N/A
BICO Group AB
STO:BICO
Cash Equivalents
kr861m
CAGR 3-Years
26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genovis AB
STO:GENO
Cash Equivalents
kr135.8m
CAGR 3-Years
48%
CAGR 5-Years
72%
CAGR 10-Years
41%
MedCap AB (publ)
STO:MCAP
Cash Equivalents
kr287.7m
CAGR 3-Years
29%
CAGR 5-Years
76%
CAGR 10-Years
15%
M
Magle Chemoswed Holding AB
STO:MAGLE
Cash Equivalents
kr7.1m
CAGR 3-Years
5%
CAGR 5-Years
26%
CAGR 10-Years
N/A
No Stocks Found

Biotage AB
Glance View

Market Cap
12.4B SEK
Industry
Life Sciences Tools & Services

Biotage AB engages in the provision of separation and synthesis technology solutions. The company is headquartered in Uppsala, Uppsala and currently employs 497 full-time employees. The company went IPO on 2000-06-30. Its customers include pharmaceutical and biotechnology companies, companies within the food industry and academic institutions. The firm offers systems and services within three areas: analytical chemistry, organic chemistry and industrial resins. Biotage’s offering within analytical chemistry consists of consumables with related applications to extract selected substances from various types of samples. The Company’s offering within organic chemistry includes products for pharmaceutical development based on both small molecules and peptides and its offering within industrial resins is composed of polymer-based resins and research services that lead to the development and manufacture of polymer-based materials. As of December 31, 2013, the Company operated 12 wholly owned subsidiaries worldwide.

BIOT Intrinsic Value
196.81 SEK
Undervaluation 21%
Intrinsic Value
Price

See Also

What is Biotage AB's Cash Equivalents?
Cash Equivalents
370m SEK

Based on the financial report for Sep 30, 2024, Biotage AB's Cash Equivalents amounts to 370m SEK.

What is Biotage AB's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
17%

Over the last year, the Cash Equivalents growth was -26%. The average annual Cash Equivalents growth rates for Biotage AB have been 1% over the past three years , 23% over the past five years , and 17% over the past ten years .

Back to Top